Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Felices

Showing results (21-30 of 77) with videos related to

Pageof 8
Sort By:
Immunity|July 25, 2006
The Tec family tyrosine kinases Itk and Rlk regulate the development of conventional CD8+ T cellsLuana O Atherly, Julie A Lucas, Martin Felices, et al.
Cancers|August 27, 2021
A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian CancerDaniel A Vallera, Felix Oh, Behiye Kodal, et al.
JCI Insight|June 21, 2022
Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustionJacob A Myers, Dawn Schirm, Laura Bendzick, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 16, 2011
Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signalingFrank Cichocki, Martin Felices, Valarie McCullar, et al.
Cancer Research and Treatment|February 24, 2017
Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated CytotoxicityJörg U Schmohl, Martin Felices, Felix Oh, et al.
Cancer Immunology Research|February 22, 2023
Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian CancerMartin Felices, Erin Wesley, Laura E Bendzick, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 31, 2014
Notch signaling at later stages of NK cell development enhances KIR expression and functional maturationMartin Felices, Dave E M Ankarlo, Todd R Lenvik, et al.
Blood Advances|March 21, 2019
Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLLMartin Felices, Behiye Kodal, Peter Hinderlie, et al.
The Journal of Biological Chemistry|October 9, 2003
A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responsesFrancis Ka-Ming Chan, Joanna Shisler, Jacqueline G Bixby, et al.
Cancer Immunology, Immunotherapy : CII|August 16, 2021
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALLSarah B Reusing, Dan A Vallera, Angela R Manser, et al.
Pageof 8

Showing results (21-30 of 77) with videos related to

Sort By:
Pageof 8
Immunity|July 25, 2006
The Tec family tyrosine kinases Itk and Rlk regulate the development of conventional CD8+ T cellsLuana O Atherly, Julie A Lucas, Martin Felices, et al.
Cancers|August 27, 2021
A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian CancerDaniel A Vallera, Felix Oh, Behiye Kodal, et al.
JCI Insight|June 21, 2022
Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustionJacob A Myers, Dawn Schirm, Laura Bendzick, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 16, 2011
Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signalingFrank Cichocki, Martin Felices, Valarie McCullar, et al.
Cancer Research and Treatment|February 24, 2017
Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated CytotoxicityJörg U Schmohl, Martin Felices, Felix Oh, et al.
Cancer Immunology Research|February 22, 2023
Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian CancerMartin Felices, Erin Wesley, Laura E Bendzick, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 31, 2014
Notch signaling at later stages of NK cell development enhances KIR expression and functional maturationMartin Felices, Dave E M Ankarlo, Todd R Lenvik, et al.
Blood Advances|March 21, 2019
Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLLMartin Felices, Behiye Kodal, Peter Hinderlie, et al.
The Journal of Biological Chemistry|October 9, 2003
A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responsesFrancis Ka-Ming Chan, Joanna Shisler, Jacqueline G Bixby, et al.
Cancer Immunology, Immunotherapy : CII|August 16, 2021
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALLSarah B Reusing, Dan A Vallera, Angela R Manser, et al.
Pageof 8